Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders. Although the complex molecular pathophysiology of neurodegeneration is largely unknown, major advances have been achieved by elucidating the genetic defects underlying mendelian forms of these diseases. This has led to the discovery of common pathophysiological pathways such as enhanced oxidative stress, protein misfolding and aggregation and dysfunction of the ubiquitin-proteasome system. Here, we describe loss-of-function mutations in a previously uncharacterized, predominantly neuronal P-type ATPase gene, ATP13A2, underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia (PARK9, Kufor-Rakeb syndrome). Whereas the wild-type protein was located in the lysosome of transiently transfected cells, the unstable truncated mutants were retained in the endoplasmic reticulum and degraded by the proteasome. Our findings link a class of proteins with unknown function and substrate specificity to the protein networks implicated in neurodegeneration and parkinsonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar phenotype has also been described in the context of loss‐of‐function mutations in the P‐type ATPase gene ATP13A2, in which recessive, early‐onset PD has been linked to defective acidification of lysosomes and insufficient autophagy (Ramirez et al, 2006).”
From Autophagy in major human diseases (2021) · cites this paper as Ramirez et al, 2006
Citations
Cites
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“By mutation screening or linkage analysis, we excluded the known autosomal recessive Parkinson disease genes and loci: PARK2 (also known as Parkin ; ref”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
The RIN: an RNA integrity number for assigning integrity values to RNA measurements
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., Granzow, M., & Ragg, T. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-3 · Cited by 2,623
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Molecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
Proteolysis: from the lysosome to ubiquitin and the proteasome
Ciechanover, A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1552 · Cited by 1,133
Evolution of Substrate Specificities in the P-Type ATPase Superfamily
Axelsen, K. B., & Palmgren, M. G. (1998) · Journal of Molecular Evolution · doi:10.1007/pl00006286 · Cited by 910
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Cited by
Items 701–800 of 1,000
PINK1 and Parkin to control mitochondria remodeling
Koh, H., & Chung, J. (2010) · Anatomy & Cell Biology · doi:10.5115/acb.2010.43.3.179 · Cited by 25
Molecular pathways and genetic aspects of Parkinson’s disease: from bench to bedside
Napoli, M. D., Shah, I. M., & Stewart, D. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.12.1693 · Cited by 24
The neuronal ceroid-lipofuscinoses (Batten disease)
Mole, S., & Schulz, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00018-2 · Cited by 19
Neurodegeneration with Brain Iron Accumulation
Schneider, S. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00042-5 · Cited by 19
Agostini, F., Sgalletta, B., & Bisaglia, M. (2024) · Cells · doi:10.3390/cells13161376 · Cited by 18
Gregori, M., Pereira, G. J. S., Allen, R., West, N., Chau, K., Cai, X., Bostock, M. P., Bolsover, S. R., Keller, M., Lee, C., et al. (2025) · The Journal of Cell Biology · doi:10.1083/jcb.202412055 · Cited by 20
Zn homeostasis in genetic models of Parkinson’s disease in Caenorhabditis elegans
Baesler, J., Kopp, J. F., Pohl, G., Aschner, M., Haase, H., Schwerdtle, T., & Bornhorst, J. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.05.005 · Cited by 20
Gialluisi, A., Reccia, M. G., Tirozzi, A., Nutile, T., Lombardi, A., Sanctis, C. D., Varanese, S., Pietracupa, S., Modugno, N., Simeone, A., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01362 · Cited by 18
Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Peña‐Altamira, E., Polazzi, E., & Monti, B. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990355 · Cited by 20
Pinto, F. D. T., Corradi, G. R., de la Hera, D. P., & Adamo, H. P. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.01.002 · Cited by 18
Does autophagy worsen or improve the survival of dopaminergic neurons?
Pasquali, L., Ruggieri, S. A., Murri, L., Paparelli, A., & Fornai, F. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70830-2 · Cited by 19
Presynaptic disorders: a clinical and pathophysiological approach focused on the synaptic vesicle
Cortès‐Saladelafont, E., Lipstein, N., & García‐Cazorla, À. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0230-z · Cited by 18
Development of a specific live-cell assay for native autophagic flux
Safren, N., Tank, E. M. H., Malik, A. M., Chua, J. P., Santoro, N., & Barmada, S. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101003 · Cited by 20
Traversing a wormhole to combat Parkinson’s disease
Caldwell, G. A., & Caldwell, K. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000257 · Cited by 19
Advances in the Genetics of P arkinson's Disease: A Guide for the Clinician
Sheerin, U., Houlden, H., & Wood, N. W. (2014) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12000 · Cited by 20
ATP13A2 (PARK9) and basal ganglia function
Croucher, K. M., & Fleming, S. M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2023.1252400 · Cited by 17
Advances in the Genetics and Epigenetics of Neurodegenerative Diseases
Coppedè, F. (2013) · Epigenetics of Degenerative Diseases · doi:10.2478/end-2012-0002 · Cited by 20
Lysosomal defects in ATP13A2 and GBA associated familial Parkinson’s disease
Sato, S., Li, Y., & Hattori, N. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1779-7 · Cited by 18
Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation
Inzelberg, R., Estrada‐Cuzcano, A., Laitman, Y., Vriendt, E. D., Friedman, E., & Jordanova, A. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181360 · Cited by 18
Dhanawat, M., Mehta, D. K., Gupta, S., & Das, R. (2020) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524920666200705222842 · Cited by 17
Methods for monitoring lysosomal morphology
Kilpatrick, B. S., Eden, E. R., Hockey, L. N., Futter, C. E., & Patel, S. (2015) · Methods in cell biology · doi:10.1016/bs.mcb.2014.10.018 · Cited by 17
Early-Onset Parkinsonism: Case Report and Review of the Literature
Al-Rumayyan, A. R., Klein, C., & Alfadhel, M. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.06.005 · Cited by 18
Kruer, M. C., Paudel, R., Wagoner, W., Sanford, L., Kara, E., Gregory, A., Foltynie, T., Lees, A. J., Bhatia, K. P., Hardy, J., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.06.036 · Cited by 17
Role of genomics in translational research for Parkinson’s disease
Sekiyama, K., Takamatsu, Y., Waragai, M., & Hashimoto, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.028 · Cited by 18
Analysis of EIF4G1 in ethnic Chinese
Li, K., Tang, B., Guo, J., Lou, M.-X., Lv, Z., Liu, Z.-H., Tian, Y., Song, C., Xia, K., & Yan, X. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-38 · Cited by 17
Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation
Martino, D., Melzi, V., Franco, G., Kandasamy, N., Monfrini, E., & Fonzo, A. D. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.036 · Cited by 17
Are we listening to everything the PARK genes are telling us?
Benson, D. L., & Huntley, G. W. (2019) · The Journal of Comparative Neurology · doi:10.1002/cne.24642 · Cited by 17
Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome
Pietrzak, A., Badura‐Stronka, M., Kangas‐Kontio, T., Felczak, P., Kozubski, W. P., Latos‐Bieleńska, A., Wierzba‐Bobrowicz, T., & Florczak‐Wyspianska, J. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.88459 · Cited by 17
RNA Biomarkers of Parkinson‘s Disease: Developing Tools For Novel Therapies
Hennecke, G., & Scherzer, C. R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.1.41 · Cited by 17
Pathology of Parkinson's Disease
Halliday, G. M., & Murphy, K. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00009-x · Cited by 20
Dystonia genes and their biological pathways
Fonzo, A. D., Jinnah, H. A., & Zech, M. (2023) · International review of neurobiology · doi:10.1016/bs.irn.2023.04.009 · Cited by 16
Awad, P. S., dos Santos, D. T., Santos‐Lobato, B. L., Camargos, S., Cornejo‐Olivas, M., Rieder, C. R. D. M., Mata, I. F., Chaná‐Cuevas, P., Klein, C., & Schuh, A. F. S. (2023) · Movement Disorders · doi:10.1002/mds.29614 · Cited by 21
Plasma exosomes impair microglial degradation of α‐synuclein through V‐ATPase subunit V1G1
Li, Y., Wang, Y., Kou, L., Yin, S., Chi, X., Sun, Y., Wu, J., Jin, Z., Zhou, Q., Zou, W., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14738 · Cited by 19
Nyuzuki, H., Ito, S., Nagasaki, K., Nitta, Y., Matsui, N., Saitoh, A., & Matsui, H. (2020) · IBRO Reports · doi:10.1016/j.ibror.2020.05.002 · Cited by 16
Mahmood, A., Shah, A. A., Umair, M., Wu, Y., & Khan, A. U. (2021) · Clinical Genetics · doi:10.1111/cge.14019 · Cited by 17
Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy
Debnath, M., Dey, S., Sreenivas, N., Pal, P. K., & Yadav, R. (2022) · Annals of Neurosciences · doi:10.1177/09727531221089396 · Cited by 17
The Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
Spinal cord and parkinsonism: Neuromorphological evidences in humans and experimental studies
Vivacqua, G., Casini, A., Vaccaro, R., Salvi, E. P., Pasquali, L., Fornai, F., Yu, S., & D’Este, L. (2011) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2011.03.001 · Cited by 16
Kim, K., & Yim, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.011 · Cited by 16
Mao, X.-Y., Burgunder, J., Zhang, Z.-J., Chang, X. L., Peng, R., Burgunder, J., Yang, Y., Wang, Y.-C., Li, T., & Zhang, Z.-J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.11.010 · Cited by 16
Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis
Rayaprolu, S., Seven, Y. B., Howard, J. C., Duffy, C., Altshuler, M. S., Moloney, C. M., Giasson, B. I., & Lewis, J. M. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.05.009 · Cited by 18
GCH1 mutations in hereditary spastic paraplegia
Varghaei, P., Yoon, G., Estiar, M. A., Veyron, S., Léveillé, E., Dupré, N., Trempe, J., Rouleau, G. A., & Gan‐Or, Z. (2021) · Clinical Genetics · doi:10.1111/cge.13955 · Cited by 16
Genetic heterogeneity of early onset Parkinson disease: The dilemma of clinico-genetic correlation
Rajan, R., Holla, V. V., Kamble, N. L., Yadav, R., & Pal, P. K. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107146 · Cited by 16
Biomarkers for detection, prognosis and therapeutic assessment of neurological disorders
Singh, S. G., Gupta, S. K., & Seth, P. K. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0097 · Cited by 16
Lessons from metabolic perturbations in lysosomal storage disorders for neurodegeneration
Medoh, U. N., Chen, J. Y., & Abu-Remaileh, M. (2021) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2021.100408 · Cited by 16
Mitochondrial Regulation by PINK1-Parkin Signaling
Imai, Y. (2012) · ISRN Cell Biology · doi:10.5402/2012/926160 · Cited by 17
Eye movement disorders in ATP13A2 mutation carriers (PARK9)
Machner, B., Sprenger, A., Behrens, M. I., Ramírez, A., Brüggemann, N., Klein, C., & Helmchen, C. (2010) · Movement Disorders · doi:10.1002/mds.23352 · Cited by 15
Self-citationAssociation study of SCARB2 rs6812193 polymorphism with Parkinson's disease in Han Chinese
Chen, D., Zhang, Y., Chen, W., Wang, Y., Liu, J., Rong, T., Ma, J., Wang, G., Zhang, J., Pan, J., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.035 · Cited by 15
CATP-6, a C. elegans Ortholog of ATP13A2 PARK9, Positively Regulates GEM-1, an SLC16A Transporter
Lambie, E. J., Tieu, P. J., Lebedeva, N., Church, D. L., & Conradt, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077202 · Cited by 15
Shen, T., Pu, J., Lai, H., Xu, L., Si, X., Yan, Y., Jiang, Y., & Zhang, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-32217-4 · Cited by 15
Ren, X., & Butterfield, D. A. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.004 · Cited by 16
Fei, Q.-Z., Cao, L. H., Xiao, Q., Zhang, T., Zheng, L., Wang, X., Wang, G., Zhou, H., Wang, Y., & Chen, S. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.018 · Cited by 16
Rapid screening of ATP13A2 variant with high‐resolution melting analysis
Funayama, M., Tomiyama, H., Wu, R., Ogaki, K., Yoshino, H., Mizuno, Y., & Hattori, N. (2010) · Movement Disorders · doi:10.1002/mds.23106 · Cited by 15
Shen, Y., Guo, X., Han, C., Wan, F. J., Ma, K., Guo, S., Wang, L., Xia, Y. F., Liu, L., Lin, Z., et al. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2549-2 · Cited by 15
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Wu, R., Lin, C., & Lin, H.-I. (2014) · Neurology · doi:10.1212/wnl.0000000000000004 · Cited by 16
Massari, C. M., Dues, D. J., Bergsma, A. L., Sipple, K., Frye, M. A., Williams, E. T., & Moore, D. J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106701 · Cited by 14
Samaddar, M., Fitzgerald, G. A., Nguyen, A. H., Davis, S. S., Jain, S., Guo, J., Propson, N. E., van Lengerich, B., Shi, Y., Balasundar, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116179 · Cited by 14
RetractedGenetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease
Wu, G., Pang, S., Feng, X., Zhang, A., Li, J., Gu, K., Huang, J. A., Dong, H., & Yan, B. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.238 · Cited by 15
Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose
Li, J., Li, S., Zhang, L., Ouyang, L., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.5803 · Cited by 18
Modi, P., Ayajuddin, M., Phom, L., Koza, Z., Das, A., Chaurasia, R., Samadder, S., Achumi, B., ., M., Pukhrambam, R. S., et al. (2016) · InTech eBooks · doi:10.5772/63767 · Cited by 15
α -Synuclein Trafficking in Parkinson’s Disease: Insights From Fly and Mouse Models
Cheng, J., Lu, Q., Li, S., & Ho, M. S.-C. (2018) · ASN NEURO · doi:10.1177/1759091418812587 · Cited by 16
Recent insights into the networking of CLN genes and proteins in mammalian cells
Huber, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15822 · Cited by 16
Pain in monogenic Parkinson’s disease: a comprehensive review
Alizadeh, P., Terroba‐Chambi, C., Achen, B., & Bruno, V. A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1248828 · Cited by 14
Post-translational modification and mitochondrial function in Parkinson’s disease
Luo, S., Wang, D., & Zhang, Z. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1329554 · Cited by 17
Mutation analysis for DJ-1 in sporadic and familial parkinsonism: Screening strategy in parkinsonism
Tomiyama, H., Li, Y., Yoshino, H., Mizuno, Y., Kubo, S., Toda, T., & Hattori, N. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.033 · Cited by 14
Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population
Wang, L., Guo, J., Zhang, W., Xu, Q., Zuo, X., Shi, C., Luo, L.-Z., Liu, J., Hu, L., Hu, Y., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.02.037 · Cited by 14
From Genes to Proteins in Mendelian Parkinson's Disease: An Overview
Cetinkaya, C. P., Lesage, S., Brice, A., & Başak, A. N. (2009) · The Anatomical Record · doi:10.1002/ar.20968 · Cited by 15
Furune, T., Hashimoto, K., & Ishiguro, J. (2008) · Genes & Genetic Systems · doi:10.1266/ggs.83.373 · Cited by 14
ATP13A2 and Alpha-synuclein: a Metal Taste in Autophagy
da Fonseca, T. L., & Outeiro, T. F. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.4.314 · Cited by 15
Phenotypic assays in yeast and zebrafish reveal drugs that rescue ATP13A2 deficiency
Heins-Marroquin, U., Jung, P. P., Cordero-Maldonado, M. L., Crawford, A. D., & Linster, C. L. (2019) · Brain Communications · doi:10.1093/braincomms/fcz019 · Cited by 14
Jellinger, K. A. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch21 · Cited by 15
LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease
Patra, B., Parsian, A. J., Racette, B. A., Zhao, J. H., Perlmutter, J. S., & Parsian, A. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.05.004 · Cited by 16
Unveiling the hidden players: noncoding RNAs orchestrating polyamine metabolism in disease
Rossi, M. N., Fiorucci, C., Mariottini, P., & Cervelli, M. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01235-3 · Cited by 13
Genetically encoded fluorescent reporter for polyamines
Sharma, P., Kim, C. Y., Keys, H. R., Imada, S., Joseph, A. B., Ferro, L. S., Kunchok, T., Anderson, R., Sun, Y., Yilmaz, Ö. H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60147-z · Cited by 14
Zielich, J., Tzima, E., Schröder, E. A., Jemel, F., Conradt, B., & Lambie, E. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194451 · Cited by 13
Psychiatric Manifestations of ATP13A2 Mutations
Balint, B., Damásio, J., Magrinelli, F., Guerreiro, R. J., Brás, J., & Bhatia, K. P. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13034 · Cited by 13
Animal Models of Autosomal Recessive Parkinsonism
Bastioli, G., Regoni, M., Cazzaniga, F. A., Luca, C. M. G. D., Bistaffa, E., Zanetti, L., Moda, F., Valtorta, F., & Sassone, J. (2021) · Biomedicines · doi:10.3390/biomedicines9070812 · Cited by 13
Jerez, P. Á., Alcantud, J. L., Reyes‐Ramírez, L. D. L., Moore, A. K., Ruz, C., Montero, F. V., Rodríguez-Losada, N., Saini, P., Gan‐Or, Z., Alvarado, C. X., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00496-y · Cited by 14
Yeast as a Tool for Deeper Understanding of Human Manganese-Related Diseases
Thines, L., Deschamps, A., Stříbný, J., & Morsomme, P. (2019) · Genes · doi:10.3390/genes10070545 · Cited by 15
Genetic association study of the P‐type ATPase ATP13A2 in late‐onset Parkinson's disease
Raković, A., Stiller, B., Djarmati, A., Flaquer, A., Freudenberg, J., Toliat, M. R., Linnebank, M., Kostić, V., Lohmann, K., Paus, S., et al. (2008) · Movement Disorders · doi:10.1002/mds.22399 · Cited by 13
Self-citationFBXO7 gene mutations may be rare in Chinese early-onset Parkinsonism patients
Luo, L.-Z., Xu, Q., Guo, J., Wang, L., Shi, C., Wei, J., Long, Z., Pan, Q., Tang, B., Xia, K., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.06.083 · Cited by 13
Iron chelators as mitophagy agents: Potential and limitations
Brogyányi, T., Kejík, Z., Veselá, K., Dytrych, P., Hoskovec, D., Masařík, M., Babula, P., Kaplánek, R., Přibyl, T., Zelenka, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117407 · Cited by 12
Clinical Overview and Phenomenology of Movement Disorders
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50004-8 · Cited by 15
ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway
Hatori, Y., Kanda, Y., Nonaka, S., Nakanishi, H., & Kitazawa, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276823 · Cited by 12
ATP13A2 Gene Silencing in Drosophila Affects Autophagic Degradation of A53T Mutant α-Synuclein
Dhanushkodi, N. R., Khair, S. B. A., Ardah, M. T., & Haque, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021775 · Cited by 13
A Genome‐wide Scan in an Amish Pedigree with Parkinsonism
Lee, S. L., Murdock, D. G., McCauley, J. L., Bradford, Y., Crunk, A. E., McFarland, L. L., Jiang, L., Wang, T., Schnetz‐Boutaud, N. C., & Haines, J. L. (2008) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2008.00452.x · Cited by 12
Brás, J., & Schneider, S. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-17223-1 · Cited by 12
The strategic function of the P5-ATPase ATP13A2 in toxic waste disposal
Pinto, F. D. T., & Adamo, H. P. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.11.008 · Cited by 12
Depression in multiple sclerosis patients associated with risk variant near NEGR1
Brugger, S. W., Gardner, M., Beales, J. T., Briggs, F. B. S., & Davis, M. F. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102537 · Cited by 13
TCS in Monogenic Forms of Parkinson’s Disease
Brockmann, K., & Hagenah, J. M. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)90011-1 · Cited by 12
Autosomal Recessive Mutations in the Development of Parkinson‘s Disease
Lopez, G. J., & Sidransky, E. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.96 · Cited by 13
The Role of Neuroinflammation in Parkinson's Disease
Chen, X., & Tansey, M. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-384913-7.00018-6 · Cited by 13
Polyamines buffer labile iron to suppress ferroptosis
Sharma, P., Keys, H. R., Mansell, R. P., Stark, J., Girard, L., Ausler, C., Anderson, R., Müller, S., Imada, S., Pires, I. S., et al. (2026) · Cell · doi:10.1016/j.cell.2026.07.040 · Cited by 12
Bridging between transplantation therapy and neurotrophic factors in Parkinson s disease
Smith, G. M. (2014) · Frontiers in Bioscience-Elite · doi:10.2741/e704 · Cited by 11
ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma
Huang, J., Xu, S., Zhou, Y., Zheng, Y., Yang, B., & Ou, Q. (2022) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05099-7 · Cited by 11
Early-onset autosomal-recessive parkinsonian-pyramidal syndrome.
Lai, H., Lin, C., & Wu, R. (2012) · PubMed · Cited by 11
Alpha-synuclein truncation and disease
Ritchie, C. M., & Thomas, P. (2012) · Health · doi:10.4236/health.2012.431175 · Cited by 11
A Lysosomal Lair for a Pathogenic Protein Pair
Dawson, T. M., & Dawson, V. L. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002808 · Cited by 13
Reduction of the P5A-ATPase Spf1p phosphoenzyme by a Ca2+-dependent phosphatase
Corradi, G. R., Mazzitelli, L. R., Petrovich, G. D., Grenón, P., Sørensen, D. M., Palmgren, M. B., Pinto, F. D. T., & Adamo, H. P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232476 · Cited by 11
An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease
Schechter, M., & Sharon, R. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212684 · Cited by 11
Metadata
- Authors
- Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., Al-Din, A., Hillmer, A. M., Karsak, M., Liss, B., Woods, C. G., Behrens, M. I., & Kubisch, C.
- Affiliations
- University of Cologne (DE)
- Philipps University of Marburg (DE)
- University of Leeds (GB)
- Centro de Estudios Científicos (CL)
- University of Bonn (DE)
- King Hussein Medical Center (JO)
- Pinderfields Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Kubisch, Christian
- ORCID
- Venue
- Nature Genetics
- Published
- 2006-09-10
- Volume
- 38
- Issue
- 10
- Pages
- 1184-1191
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2139369185
- Cited by
- 1,208
- References
- 30
- Citations by year
- 2026: 42 · 2025: 44 · 2024: 39 · 2023: 49 · 2022: 45 · 2021: 70 · 2020: 73 · 2019: 69 · 2018: 54 · 2017: 64 · 2016: 76 · 2015: 59 · 2014: 57 · 2013: 71 · 2012: 64
- FWCI
- 38.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Universidad de Chile (submittedVersion)
- Funders
- Tinker Foundation
- Wellcome Trust
- Royal Society
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Rheinische Friedrich-Wilhelms-Universität Bonn
- National Institutes of Health
- Directorate for Biological Sciences
- National Institute of Child Health and Human Development
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- ATP13A2, P-type ATPase, Kufor-Rakeb syndrome, PARK9, autosomal recessive inheritance, loss-of-function mutations, neurodegeneration, endoplasmic reticulum retention, proteasomal degradation, protein misfolding
- MeSH terms
- Adenosine Triphosphatases, Dementia, Endoplasmic Reticulum, Female, Proton-Translocating ATPases, Humans, Lysosomes, Male, Mesencephalon, Mutation, Neurons, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.